Zeiser, R. Et Al. 2025. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. Journal of Clinical Oncology , vol.43, no.23 , 2566-2571.

Zeiser, R., Russo, D., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., ... Musso, M.(2025). Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. Journal of Clinical Oncology , vol.43, no.23, 2566-2571.

Zeiser, Robert Et Al. "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study," Journal of Clinical Oncology , vol.43, no.23, 2566-2571, 2025

Zeiser, Robert Et Al. "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study." Journal of Clinical Oncology , vol.43, no.23, pp.2566-2571, 2025

Zeiser, R. Et Al. (2025) . "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study." Journal of Clinical Oncology , vol.43, no.23, pp.2566-2571.

@article{article, author={Robert Zeiser Et Al. }, title={Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study}, journal={Journal of Clinical Oncology}, year=2025, pages={2566-2571} }